XML 38 R25.htm IDEA: XBRL DOCUMENT
v3.21.1

SEGMENT AND ENTERPRISE-WIDE INFORMATION | 12 Months Ended
--- | ---
Apr. 03, 2021
Segment Reporting [Abstract] |
SEGMENT AND ENTERPRISE-WIDE INFORMATION | SEGMENT AND ENTERPRISE-WIDE INFORMATION The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Historically, the Company's operating segments were based primarily on geography. Effective as of March 31, 2019, the Company completed the transition of its operating structure to three global business units and accordingly, reorganized its reporting structure to align with its three global business units and the information that will be regularly reviewed by the Company's chief operating decision maker. Following the reorganization, the Company's reportable segments are as follows: •Plasma •Blood Center •Hospital Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, gains and losses on dispositions and sale of assets, asset impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation, transaction and integration costs and certain tax settlements and unusual or infrequent and material litigation-related charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis. Selected information by reportable segment is presented below:
(In thousands) | 2021 |  | 2020 |  | 2019
Net revenues |  |  |  |  |
Plasma | $ | 333,334 |  |  | $ | 460,637 |  |  | $ | 426,781 |
Blood Center | 307,370 |  |  | 325,661 |  |  | 335,557 |
Hospital | 210,606 |  |  | 194,604 |  |  | 190,821 |
Net revenues by business unit | 851,310 |  |  | 980,902 |  |  | 953,159 |
Service (1) | 20,758 |  |  | 19,830 |  |  | 19,906 |
Effect of exchange rates | (1,605) |  |  | (12,253) |  |  | (5,486) |
Net revenues | $ | 870,463 |  |  | $ | 988,479 |  |  | $ | 967,579 |
(1) Reflects revenue for service, maintenance and parts. |  |  |  |  |
(In thousands) | 2021 |  | 2020 |  | 2019
Segment operating income |  |  |  |  |
Plasma | $ | 172,463 |  |  | $ | 225,351 |  |  | $ | 180,300 |
Blood Center | 141,962 |  |  | 159,802 |  |  | 163,628 |
Hospital | 84,066 |  |  | 80,669 |  |  | 76,338 |
Segment operating income | 398,491 |  |  | 465,822 |  |  | 420,266 |
Corporate expenses (1) | (256,751) |  |  | (255,727) |  |  | (263,603) |
Effect of exchange rates | 12,830 |  |  | 7,920 |  |  | 8,367 |
Deal amortization | (32,830) |  |  | (25,746) |  |  | (24,803) |
Impairment of assets, PCS2 accelerated depreciation and other related charges | (25,696) |  |  | (75,750) |  |  | (40,296) |
Transaction and Integration costs | (18,421) |  |  | (568) |  |  | — |
Restructuring and turnaround costs | (15,661) |  |  | (19,878) |  |  | (13,660) |
European Medical Device Regulation costs and other | (4,130) |  |  | (1,506) |  |  | — |
Litigation-related charges | (897) |  |  | 701 |  |  | (2,726) |
Gains on divestitures and sale of assets | 32,812 |  |  | 8,083 |  |  | — |
Operating income | $ | 89,747 |  |  | $ | 103,351 |  |  | $ | 83,545 |
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
(In thousands) | 2021 |  | 2020 |  | 2019
Depreciation and amortization |  |  |  |  |
Plasma | $ | 24,093 |  |  | $ | 63,347 |  |  | $ | 61,721 |
Blood Center | 39,672 |  |  | 38,429 |  |  | 38,074 |
Hospital | 20,522 |  |  | 8,513 |  |  | 9,623 |
Total depreciation and amortization (excluding impairment charges) | $ | 84,287 |  |  | $ | 110,289 |  |  | $ | 109,418 |
(In thousands) | April 3, 2021 |  | March 28, 2020 |  | March 30, 2019
Long-lived assets(1) |  |  |  |  |
Plasma | $ | 105,599 |  |  | $ | 141,903 |  |  | $ | 192,628 |
Blood Center | 83,225 |  |  | 93,758 |  |  | 127,272 |
Hospital | 28,735 |  |  | 17,738 |  |  | 24,079 |
Total long-lived assets | $ | 217,559 |  |  | $ | 253,399 |  |  | $ | 343,979 |
(1) Long-lived assets are comprised of property, plant and equipment.
Selected information by principle operating regions is presented below:
(In thousands) | April 3, 2021 |  | March 28, 2020 |  | March 30, 2019
Long-lived assets(1) |  |  |  |  |
United States | $ | 159,749 |  |  | $ | 186,488 |  |  | $ | 269,849 |
Japan | 1,515 |  |  | 2,037 |  |  | 1,726 |
Europe | 10,384 |  |  | 10,143 |  |  | 11,200 |
Asia | 30,588 |  |  | 29,175 |  |  | 30,930 |
Other | 15,323 |  |  | 25,556 |  |  | 30,274 |
Total long-lived assets | $ | 217,559 |  |  | $ | 253,399 |  |  | $ | 343,979 |
(1) Long-lived assets are comprised of property, plant and equipment.
(In thousands) | 2021 |  | 2020 |  | 2019
United States | $ | 522,607 |  |  | $ | 646,204 |  |  | $ | 606,845 |
Japan | 77,676 |  |  | 72,218 |  |  | 69,908 |
Europe | 159,077 |  |  | 153,347 |  |  | 164,504 |
Asia | 105,820 |  |  | 109,295 |  |  | 118,700 |
Other | 5,283 |  |  | 7,415 |  |  | 7,622 |
Net revenues | $ | 870,463 |  |  | $ | 988,479 |  |  | $ | 967,579 |
Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments. Net revenues by product line are as follows:
(In thousands) | 2021 |  | 2020 |  | 2019
Plasma products and services | 414,266 |  |  | 537,231 |  |  | 501,837 |
Blood Center products and services | 239,614 |  |  | 252,829 |  |  | 269,203 |
Hospital products and services | 216,583 |  |  | 198,419 |  |  | 196,539 |
Net revenues | $ | 870,463 |  |  | $ | 988,479 |  |  | $ | 967,579 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration